Genes predict GLP‑1 results

Your gut already makes a hormone called glucagon-like peptide 1 after you eat, and that hormone tells your brain you’re full and tells your stomach to empty more slowly. Drugs like semaglutide copy that signal, which is why they can lower appetite and body weight at the same time. (nejm.org) That same slowdown in digestion is also why many people get nausea, vomiting, constipation, or diarrhea on these medicines. In real-world use, some people lose less than 5% of their body weight while others lose more than 20%, even when they take drugs from the same family. (nejm.org) (medicalxpress.com) A gene is a stretch of DNA that works like an instruction line in a recipe, and tiny spelling changes in that recipe can make the same drug hit a little harder or a little softer. That is what researchers went looking for in a new study of 27,885 people who reported taking glucagon-like peptide 1 medicines for obesity. (nature.com) (statnews.com) The data came from 23andMe participants who answered surveys about weight loss and side effects, and the researchers then scanned their genomes for repeated patterns. That kind of scan is called a genome-wide association study, which is basically a giant compare-and-contrast search across millions of DNA markers. (nature.com 1) (nature.com 2) One of the clearest signals showed up in a gene called GLP1R, which makes the receptor that these drugs are designed to hit. People carrying a specific GLP1R variant lost more weight on average, and Bloomberg reported the effect at about 1.7 extra pounds for each copy of that variant. (nature.com) (bloomberg.com) The same study also found DNA signals tied to side effects in GLP1R and in another gene called GIPR. GIPR helps cells respond to a second gut hormone, glucose-dependent insulinotropic polypeptide, which matters because tirzepatide works on both the glucagon-like peptide 1 pathway and the glucose-dependent insulinotropic polypeptide pathway. (nature.com) (springernature.com) That GIPR result was especially tied to nausea and vomiting in people taking tirzepatide, not just any drug in the class. In other words, one DNA change looked less like a general “weight-loss drug” effect and more like a clue about which specific medicine a person may tolerate. (nature.com) (scientificamerican.com) The effect sizes were real but not huge, which means DNA is not destiny here. Scientists quoted by Nature and Scientific American said genetics explains only part of the variation, alongside dose, diet, other illnesses, and whether side effects make someone eat less or stop treatment early. (nature.com) (scientificamerican.com) The practical idea is not that a cheek swab will pick one perfect drug tomorrow morning. The nearer-term use is a broader prediction model that mixes genetics with age, sex, and clinical history to sort patients into groups with higher odds of strong weight loss or higher odds of rough stomach side effects. (23andme.com) (nature.com) That still needs follow-up in more diverse groups, because this study relied on self-reported outcomes from one research cohort rather than head-to-head clinic measurements. But it is one of the first large demonstrations that the same genes involved in these drugs’ targets also help predict who gets more benefit and who gets sicker taking them. (nature.com 1) (nature.com 2)